The Committee for Medicinal Products on Human Use (CHMP) of the European Medicines Agency (EMA) has completed its review of the benefit/risk balance of buflomedil and has come to a negative conclusion. The EMA recommends that all marketing authorisations for medicines containing buflomedil should be suspended throughout the Member States of the EU.

risk information - full text (available in German only)